Frank Vinluan interviewed our CEO, Dan Mandell, PhD, on GRO Biosciences’ platform for engineering therapeutic proteins without the immune reactions that often impair safety and efficacy, and how the Company’s lead program is a potential competitor to a therapy for gout that Amgen acquired in a multi-billion-dollar deal.
From the article: “For gout pain that does not respond to conventional therapies, patients’ only remaining option is a drug from Amgen. But this biologic medicine introduces the same problem facing every therapeutic protein: The body can see the engineered protein as foreign, prompting an immune response that renders the treatment ineffective. The technology of GRO Biosciences engineers proteins that the immune system sees as belonging to the body. The biotech startup aims to overcome the immune response limitation of the Amgen drug and it has raised $60 million for its technology’s first test in humans.”
